Fintel on MSN11h
Wedbush Downgrades Sutro Biopharma (STRO)Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...
John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...
BofA downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11, following the company’s announcement ...
MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...
Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ...
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or ...
As we reflect on five years of COVID-19, it’s clear that the impacts are still unfolding. The life sciences—and we as ...
Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...
Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith ...
Barchart on MSN2d
Benitec - Another Biopharma RocketYour FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback